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PRELIMINARY RESULTS OF PHASE II TRIAL OF CLOFARABINE WITH
PARENTERAL BUSULFAN FOLLOWED BY ALLOGENEIC RELATED OR UN-
RELATED DONOR TRANSPLANTATION FOR THE TREATMENT OF HEMA-
TOLOGIC MALIGNANCIES AND DISEASES
Agura, E.D., Berryman, R.B., Fay, J.W., Pineiro, L.A., Vance, E.A.,
Tadic-Ovcina, M. Charles A. Sammons Cancer Center, Dallas, TX.
Background:Nonablative transplant regimens are useful to treat
patients who are elderly or too ill to undergo a full-intensity ablative
allogeneic transplant regimen. However, this approach is limited by
a higher relapse rate in some situations. We developed a novel con-
ditioning regimen using the nucleoside analogue clofarabine (CLO)
with busulfan (BU) to treat elderly patients with acute leukemia or
high risk MDS who are not in remission or are at high risk of re-
lapse.Methods: Seven patients were enrolled on this single institu-
tion; phase II, IRB-approved trial, so far. The diagnoses at the time
of transplant were four with AML, one with ALL, and two with
MDS. At the time of study entry, six patients had persistent/relapsed
disease and one was in remission. All patients received CLO 40 mg/
m2/day iv on d-8 through d-4 followed by BU 3.2 mg/m2/day iv on
d-3 and -2, followed by infusion of HLA matched related or unre-
lated donor PBSC on day 0. GVHD prophylaxis consisted of oral
FK506 andMTX5mg/m2 iv d1 1,13 and16. BU andCLOphar-
macokinetic samples were collected on all patients for later PK anal-
ysis. Results: Primary endpoints included toxicity and response to
therapy. There were no cases of hepatic, cardiac, or renal toxicity at-
tributed to the conditioning regimen by d1 30. Acute toxicities in-
cluded hand/foot syndrome, n5 2 (one grade 1, and one grade 3 by
CTCAE v 3.0); fluid retention, n5 3 (2 grade 1 and 1 grade 2); nau-
sea n5 5 (four grade 1 and 1 gr 2). One subject suffered respiratory
failure of unknown etiology. That resolved completely and was
deemed to be possibly related to the treatment. All patients had he-
matologic nadirs lasting 12 to 15 days. GCSFwas used in 6 of 7 sub-
jects. 7 of 7 patients achieved allogeneic engraftment with myeloid
cells by day130. Response to therapy was documented in 5 patients
by d1 30, two are not yet evaluated. One (1) patient relapsed by d1
62, one relapsed by day154. 3 of 5 remain in remission with follow
up ranging from 91 to 152 days.Conclusions:CLO1BU is a novel
allogeneic conditioning regimen that seems to be well tolerated by
the small number of subjects treated so far at our institution. The
follow up is not long enough to conclude more at this time. The
study continues to accrue patients and will be updated at the meet-
ing.334
NON-MYELOABLATIVE TRANSPLANTATION IS A FEASIBLE OPTION IN
PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES: A SIN-
GLE CENTER EXPERIENCE
Ganguly, S., Vaka, S., Divine, C.L., Deauna-Limayo, D.,
Bodensteiner, D.C., Skikne, B.S. University of Kansas Medical Center,
Kansas City, KS.
Introduction: There are limited therapeutic options in patients
with advanced hematologic diseases. Historically patients with re-
lapsed/refractory disease do not fare well after non-myeloablative
allogeneic stem cell transplantation (NST). Methods: In an at-
tempt to examine whether NST provides disease control in patients
with high risk hematologic malignancies, we retrospectively evalu-
ated our experience and analyzed the outcomes of NST in patients
with high risk hematologic malignancies from 1999 to 2006. Re-
sults: Ten males and 4 females (n 5 14) of median age 48 years
(range: 19–65 years) were treated. Of these, only 4 patients were
in complete remission (CR) at the time of transplantation and 10 pa-
tients were transplanted with active disease. All patients (n 5 4) in
CR at the time of transplantation had received one or two prior
myeloablative stem cell transplantation. Themajority of patients re-
ceived peripheral blood stem cells (n 5 12). One patient received
bone marrow and one patient received cord blood derived stem
cells. All patients engrafted. Median time for neutrophil recovery
was 18 days (range: 10–29 days) and 22 days (range: 14–47 days)
for platelets. In two patients, the platelet count did not drop below
20 103/ml and two patients died prior to platelet engraftment.Me-dian duration of follow-up for those who did not succumb to early
transplant-related mortality (\100 days) was 5.2 months (range:
105 days-2 years). Median survival time of this cohort was 125
days. Of the 14 patients, 9 have died. Four patients (30%) died
within 100-days of transplantation. Overall survival (OS) of all pa-
tients who did not succumb to TRMwas 44% at 14 months. No re-
lapse occurred after 6 months. All 5 patients that are alive have
chronic graft versus host disease. OS in patients transplanted in
CR (n5 4) at 1-year was 50%, and was 44% for those transplanted
with active disease (n 5 10). Disease status at transplantation was
not a significant variable for survival (p5 0.88).Most frequent cause
of death was relapse/progression of disease (n 5 5; 55%). Conclu-
sion: In conclusion, NST provides a possible therapeutic option in
a proportion of patients with high risk hematologic malignancies.
Disease relapse prior to development of graft versus tumor effect re-
mains the most frequent cause of failure in patients transplanted
with active disease.335
RADIATION FOLLOWED BY MYLOTARG PLUS DLI FOR EXTRAMEDUL-
LARY RELAPSE FROM ACUTE MYELOID LEUKEMIA POST-ALLOGENEIC
TRANSPLANT
Sharma, M., Cumpston, A., Craig, M. West Virginia University, Mor-
gantown, WV.
Introduction: Extramedullary relapse of acute leukemia after he-
matopoietic cell transplant can occur in the formof granulocytic sar-
comas and leukemia cutis. According to some published reports,
they may occur in up to 20% of post-transplant patients. The treat-
ment of these relapses has been center dependent, and no treatment
protocol has been published which clearly shows superiority. We
describe three patientswith extramedullary relapsewhowere treated
with a combination of radiation, gemtuzumab ozogamicin and DLI
(donor leukocyte infusion).Methods: All three patients had a diag-
nosis of AML and had induction and consolidation therapy, fol-
lowed by a myeloablative transplant with cytoxan and TBI as
a preparative regimen. Two patients presented with chloromas
and one presented with leukemia cutis as sites of recurrence.
None had evidence of bone marrow recurrence, and relapse oc-
curred from 4 – 11 months post transplant. All three were treated
with focal radiation therapy to the site of relapse followed by gem-
tuzumab ozogamicin andDLI. The radiation doses were 20–30Gy,
followed by gemtuzumab ozogamicin 9 mg/m2 given every two
weeks for two doses. All three patients received DLI initially at
1.0  10–7 CD31 cells/kg, and subsequently dose-escalated to
2.0  10–7. Results: All three patient achieved disease response.
Median disease free survival has not been reached. One patient
with leukemia cutis died of complication from acute GVHD 9
months after the first dose of DLI. The remaining two patients
with chloromas are still alive and free of marrow relapse after two
doses of DLI.Conclusion:The combination of focal radiation fol-
lowed by gemtuzumab ozogamicin (9 mg/m2) every two weeks for
two doses, followed by dose escalating DLI is an option for patients
with extramedullary relapse of acute leukemia following hemato-
poietic cell transplantation.GVH/GVL336
RELATIVE CONTRIBUTION OF CD127 NEGATIVE SELECTION, RAPAMY-
CIN, ANDTGF-b TO THEGENERATIONOFHUMANREGULATORY T CELLS
THAT INHIBIT ALLOREACTIVITY VIA DENDRITIC CELL MODULATION
Amarnath, S.1, Foley, J.1, Mariotti, J.1, Costanzo, C.M.1, Ryan, K.1,
Fong, T.2, Warner, N.2, Fowler, D.H.1. 1Center for Cancer Research,
National Cancer Institute, National Institute of Health, Bethesda, MD;
2BD Biosciences, San Jose, CA.
Regulatory T cells (Tregs) express reduced IL-7Ra (CD127) and
preferentially expand in rapamycin or TGF-b. Here, we evaluated
the independent and combined effect of CD127 negative selection,
124 Poster Session IIrapamycin, and TGF- b on human Treg cell generation ex vivo.
Normal donor CD4 T cells were isolated by CD4 positive selection
and CD41CD127- cells were isolated by CD127 negative selection
and CD4 positive selection. Relative to total CD4 T cells,
CD41CD127- cells were enriched for the Treg transcription fac-
tor, Foxp3 (n5 8 experiments; P5 0.042); and also had reduced se-
cretion of IL-2 (P5 0.05) and IFN-g (P5 0.03). Both subsets were
expanded using anti-CD3, anti-CD28 co-stimulation and IL-2 6
rapamycin and 6 TGF-b. Relative to culture input of total CD4
cells, input of CD41CD127- cells were potent suppressors at day
12, asmeasured by inhibition of responderT cell proliferation in re-
sponse to allogeneic dendritic cell (DC) stimulation. The enhanced
capacity of CD127 negative selection to generate Tregs occurred
whether expansion was performed in rapamycin (P 5 0.02), TGF-
b (P 5 0.02), or combination of both (P 5 0.01). CD127 negative
selection alone (without rapamycin or TGF-b) was not sufficient
to generate Treg cells, as the resultant product secreted high levels
of IL-2 and IFN-g. In contrast, addition of rapamycin or TGF-b,
and in particular the combination, resulted in a Treg phenotype
as defined by: (1) high Foxp3 expression (50% CD41Foxp31);
(2) reduced Th1 cytokine secretion; and (3) suppressor function in
the allo-MLR. Transwell showed that expanded Treg cell suppres-
sionwas contact dependent.We hypothesized that such suppression
was mediated via modulation of DC function; to address this, Treg
cells and DC were co-cultured, and purified ‘‘conditioned’’ DC
were utilized as the APC source in allo-MLR. Indeed, DC condi-
tioned by Treg cells generated from CD41CD127- enriched cells
and expanded in rapamycin and TGF-b had: (1) significantly re-
duced secretion of IL-6 and TNF-a; (2) increased expression of
the inhibitory molecule PDL1; and (3) greatly reduced allostimula-
tory function; importantly, antibody blockade of DC expression of
PDL1 partially reversed the suppressive DC phenotype. In conclu-
sion, CD127- selction combined with ex vivo expansion in rapamy-
cin and TGF-b generates human Treg cells that inhibit
alloreactivity by modulating DC function. Adotive transfer of
such Tregs has implications in preventing GVHD after haemato-
poietic stem cell transplantation.337
THE PREDICTIVE VALUE OF GENE EXPRESSION PROFILES FOR ACUTE
GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANS-
PLANTATION WITH NONMYELOABLATIVE CONDITIONING FOR HEMA-
TOLOGICAL MALIGNANCY
Masmas, T.N.1, Johansen, J.V.2, Friis-Hansen, L.3, Petersen, S.L.1,
Kornblit, B.1, Winther, O.2, Nielsen, F.C.3, Vindelov, L.L.1. 1Allogeneic
Hematopoietic Cell Transplantation Laboratory, Rigshospitalet, Copenha-
gen, Denmark; 2University of Copenhagen, Copenhagen, Denmark;
3Rigshospitalet, Copenhagen, Denmark.
Purpose:To test the hypothesis that global gene expression pro-
files of peripheral bloodmononuclear cells (PBMNC) day114 after
hematopoietic cell transplantation with nonmyeloablative condi-
tioning could predict the later occurrence of acute graft-versus-
host disease (GVHD) grade II-IV. Material: Between March 2000
and Marts 2006, 100 patients with hematological malignancies re-
ceived peripheral blood stem cells from an human leukocyte antigen
identical sibling/mother donor or from a matched unrelated donor
following nonmyeloablative conditioning with low dose fludarabine
and 2Gy of total body irradiation. Post-transplant immunosuppres-
sion consisted of cyclosporine and mycophenolate mofetil. Only
patients with sustained engraftment, who did not experience late-
onset acute GVHD after day 1100 were included; eight patients
were excluded due to graft rejection, three patients due to subopti-
mal RNA or lacking PBMNC samples, and further 15 patients due
to late-onset acute GVHD. Seventy-four patients were then eligible
for microarray analysis.Methods: RNA was precipitated from fro-
zen PBMNC from day114 post-transplant and gene profiling anal-
yses were performed using Human Genome U133 Plus 2.0
GeneChip Array. The array data were normalized, RMA modeled
and asinh transformed in R. The differentially regulated gene ex-
pression between the group of patients developing acute GVHD
before day140,156 and184 post-transplant compared to the pa-
tients never experiencing acute GVHD was identified and formed
the basis for the subsequent principal component analysis (PCA)and classifying models. No patients experienced acute GVHD be-
tween day185 and1100 post-transplant.Results:The patients ex-
periencing acute GVHD by different time points were separated
from the patients never experiencing acute GVHD by the PCA
plot. Furthermore, the best classifying models could separate the
groups correctly in up to 98% of cases. In addition, differentially
regulated genes between the two groups were identified. Conclu-
sion:These data suggest that the pattern of gene expression profiles
early post-transplant is able to predict patients with a high risk of
later occurrence of acute GVHD from those never experiencing
acute GVHD. This knowledge could be exploited to increase the
immunosupression and thus prevent acute GVHD in patients at
risk. Furthermore, candidate genes of interest for the pathogenesis
of acute GVHD have been identified.338
T CELL RECEPTOR GENE TRANSFER TO VIRUS-SPECIFIC T CELLS FOR
CELLULAR ANTI-TUMOR IMMUNOTHERAPY
van Loenen, M.M., Griffioen, M., van Egmond, H.M.E.,
Hagedoorn, R.S., Kester, M., Willemze, R., Falkenburg, J.H.F.,
Heemskerk,M.H.M. Leiden UniversityMedical Center, Leiden, Nether-
lands.
T cell receptor (TCR) transfer to engineer tumor specific T cells
may be an alternative strategy for adoptive immunotherapy. For
complete eradication of leukemic cells and to achieve long-term
protection, potent effector T cell function and long-termT cell per-
sistence are necessary. Therefore, we propose to use virus specific T
cells for TCR transfer since such engineered dual specific T cells
can be triggered via their endogenous TCR by latent presence of vi-
ral antigens, improving their long-term persistence. We previously
demonstrated that transfer of the minor histocompatibility antigen
HA-1 and HA-2 TCRs to CMV specific T cells led to the genera-
tion of anti-leukemic T cells with dual specificity. Based on these re-
sults, we developed a clinical grade method for generation of TCR
transferred virus T cells for cellular immunotherapy. Pentamers
combined with clinical grade available anti-biotin magnetic beads
were used to isolate CMV and EBV specific T cells. At day 3 after
isolation, T cells were transduced with multi-cistronic retroviral
vectors encoding the alpha and beta chains of the HA-2TCR linked
by an IRES or 2A-like sequence. Isolation by pentamer-coated
beads led to the generation of T cell lines with high frequencies
(.80%) of virus-specific T cells with 20–40% transduced cells.
The T cells exhibited dual specificity, and tetramer staining corre-
lated with lysis of target cells expressing endogenously-processed
HA-2. We determined whether these cells preserve their dual spec-
ificity upon repetitive stimulation. When frequent encounter of vi-
ral antigens leads to selective survival of TCR transferred T cells
predominantly expressing the CMVTCR incapable of proliferating
via the introduced TCR, persistence in vivo of TCR transferred
CMV T cells capable of controlling minimal residual disease may
fall short. We analyzed the TCR expression and functional activity
of the TCR transferred T cells after repetitive stimulation with
CMV or HA-2. TCR-transferred T cells repetitively stimulated
skewed to T cells predominantly expressing one TCR. However,
this skewing was not due to selective outgrowth, but to change of
TCR make up. This TCR make up appeared to be reversible, and
HA-2 TCR transferred CMV T cells remained their functional ac-
tivity via both TCRs after repetitive stimulation. In a clinical phase
I/II study, the safety, clinical and immunological efficacy of TCR-
transduced virus T cells as cellular anti-tumor immunotherapy
will be investigated.339
INFLIXIMAB COMBINED WITH DACLIZUMAB RESULTS IN A HIGH COM-
PLETE RESPONSE RATE WHEN USED TO TREAT ACUTE STEROID RE-
FRACTORY GRAFT-VERSUS-HOST DISEASE (SR-GVHD)
Srinivasan, R.1, Arrington, J.2, Karpovich, J.2, Donohue, T.2,
Goodwin, R.2, Ramos, C.2, Cook, L.2, Barrett, J.2, Childs, R.2. 1National
Cancer Institute, Bethesda, MD; 2National Heart, Lung and Blood Insti-
tute, Bethesda, MD.
